Introduction {#s1}
============

In patients with rheumatoid arthritis (RA), early treatment helps prevent structural joint damage, resulting in better long-term outcomes.[@R1] Recent studies suggest that a therapeutic 'window of opportunity' may exist in the early stages of RA when biologics may be more effective, due to the predominance of inflammation over joint damage.[@R4]

Certolizumab pegol (CZP) is a PEGylated, Fc-free anti-TNF. The efficacy of CZP in combination with methotrexate (MTX) has been proven in patients with established RA and insufficient response to MTX alone in the pivotal RAPID1 and RAPID2 studies (the mean disease duration was ∼6 years in both trials).[@R7] [@R8] More recently, CZP+MTX was shown to be efficacious in MTX-naïve patients with early RA and poor prognostic factors (C-OPERA study, conducted in Japan; the mean disease duration was ∼4 months),[@R9] justifying the need for a more thorough examination of the efficacy and safety of CZP+MTX in patients with recently diagnosed RA.

C-EARLY (NCT01519791) is the first randomised double-blind study to assess the efficacy and safety of CZP+MTX versus placebo (PBO)+MTX treatment over 52 weeks in inducing and sustaining clinical response, and inhibiting radiographic damage, in DMARD-naïve patients with moderate-to-severe, active RA with poor prognostic factors.

Methods {#s2}
=======

Patients {#s2a}
--------

Eligible patients were DMARD-naïve, diagnosed with RA ≤1 year prior to randomisation, fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria[@R10] and had poor prognostic factors for severe disease progression (positive for rheumatoid factor (RF) or anticitrullinated peptide antibody (ACPA) at screening). Patients must have had active RA, defined at screening and baseline (BL) as ≥4 swollen and ≥4 tender joints (out of 28); DAS28(ESR) \>3.2 and ESR ≥28 mm/h and/or C reactive protein (CRP) ≥10 mg/L (CRP at screening only).

Patients were excluded if they had received treatment for RA with any biologic or non-biologic DMARD therapy, including MTX, prior to BL. Non-steroidal anti-inflammatory drugs and oral corticosteroids (≤10 mg/day prednisone equivalent) were permitted if the BL dose was not exceeded at any point during the study.

Patients with a history of chronic or recurrent infections, serious infections, history of or active tuberculosis (TB), latent TB, malignancy or demyelinating disorders were excluded. Following a protocol amendment, TB testing methods were changed to Interferon Gamma Release Assay (IGRA) testing (QuantiFERON-TB Gold test (ELISpot test if not available)) or a purified protein derivative (PPD) skin test depending on local regulations. Patients were defined as having latent TB if they had a positive IGRA or PPD test (≥5 mm of induration) with chest imaging negative for TB infection, or a severe positive PPD reaction and a positive/indeterminate ELISpot or QuantiFERON test ≤3 months prior to screening.

Study design {#s2b}
------------

C-EARLY was a multicentre, double-blind, PBO-controlled, randomised study conducted in Europe, Australia, North America and Latin America at 181 sites (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1). Patients were randomised 3:1 to receive CZP (400 mg subcutaneously at Weeks 0, 2, 4, then 200 mg every 2 weeks to Week 52)+MTX or PBO+MTX. Randomisation at Week 0 was performed centrally using an interactive voice and web response system and was stratified by disease duration of \>4 months or ≤4 months.[@R5] Following completion of this 52-week study, patients in sustained low disease activity (sLDA; DAS28(ESR) ≤3.2 at both Weeks 40 and 52) were eligible to enter a randomised, double-blind, dose-withdrawal study (C-EARLY Period 2 (NCT01521923); to be completed in 2016). The 3:1 randomisation was used to increase the pool of CZP patients eligible for Period 2 of the study.
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Oral MTX was initiated at 10 mg/week and was escalated by 5 mg every 2 weeks, if tolerated, to a maximum of 25 mg/week (minimum 15 mg/week) by Week 8. The maximum-tolerated dose (optimised MTX) was continued through Week 52.

Patients not achieving sufficient improvement (defined as DAS28(ESR) ≤3.2 and/or ≥1.2-point improvement in DAS28 (ESR) from BL) at Weeks 20 and 24 were withdrawn to allow them to switch to a complementary medication.

All study personnel were blinded to treatment, except for a separate unblinded group who supervised/administered the study medication and determined ESR, but had no other involvement.

Statistical analysis {#s2c}
--------------------

Full details of all statistical analyses are described in the online [supplementary materials](#SM1){ref-type="supplementary-material"}. In brief, the sample size was calculated assuming an expected percentage of patients in sustained remission (sREM) at Week 52 of 50% in the CZP+MTX group and 30% in the PBO+MTX group. A minimum of 600 CZP patients and 200 PBO patients were required (for 3:1 randomisation). Hypothesis testing was performed on Week 52 data in a hierarchical manner starting with sREM, followed by the secondary endpoints in the following order: sLDA, ACR50, change from baseline (CFB) in the Health Assessment Questionnaire-Disability Index (HAQ-DI) and CFB in the van der Heijde modified total Sharp score (mTSS). All other statistical analyses are descriptive only. The full analysis set (FAS) was used for all efficacy data, except radiographic data which used the radiographic set (RAD). A logistic regression model was used for the primary and secondary Week 52 analyses and other dichotomous outcomes. CFB in HAQ-DI was analysed using analysis of covariance (ANCOVA) and CFB in mTSS was analysed using ANCOVA on the ranks.

Missing data were imputed using non-responder imputation for analyses on dichotomous outcomes and last observation carried forward for continuous outcomes.

Study procedures and evaluations {#s2d}
--------------------------------

The primary efficacy endpoint was the proportion (%) of patients in sREM (DAS28(ESR) \<2.6 at both Weeks 40 and 52). The key secondary endpoint was the proportion (%) of patients in sLDA (DAS28(ESR) ≤3.2 at both Weeks 40 and 52). Other secondary endpoints in the hierarchical testing procedure were ACR50 response, CFB in HAQ-DI and CFB in mTSS, all at Week 52.

Secondary outcomes evaluated outside the hierarchical testing procedure included: radiographic non-progression (CFB in mTSS ≤0.5) and the proportion of patients with HAQ-DI normative function (HAQ-DI ≤0.5) at Week 52, CFB in HAQ-DI, DAS28(ESR) and ACR20/50/70 responses, the proportion of patients in remission by ACR/EULAR 2011 criteria,[@R11] DAS28(ESR) \<2.6, Clinical Disease Activity Index (CDAI) ≤2.8 and Simplified Disease Activity Index (SDAI) ≤3.3 at Weeks 12, 24 and 52 (additional visits exploratory).

For the subgroup analyses, geographical regions were predefined according to their sociodemographic similarity, similar treatment guidelines (ie, EULAR/ACR treatment guidelines) and their similar patient numbers.

Safety analysis included all adverse events (AEs), serious AEs (SAEs) and clinical laboratory measurements. Incidence rates (IRs) were calculated per 100 patient-years (PY), with 95% CIs.

Results {#s3}
=======

Patient disposition and BL characteristics {#s3a}
------------------------------------------

Six hundred and sixty patients received CZP+MTX and 219 patients received PBO+MTX ([figure 1](#ANNRHEUMDIS2015209057F1){ref-type="fig"}). Of these, 655 patients in the CZP+MTX group and 213 in the PBO+MTX group were included in the FAS; 528 CZP+MTX and 163 PBO+MTX patients were included in the RAD (a summary of RAD BL radiographic characteristics is listed in online [supplementary table](#SM1){ref-type="supplementary-material"} S1). The safety set (SS) included 659 CZP+MTX and 217 PBO+MTX patients. In the randomised set (RS), the proportion of patients discontinuing treatment by Week 52 was lower in the CZP+MTX group (24.2%) than in the PBO+MTX group (34.7%). The most common reasons for discontinuation were AEs (7.7% CZP+MTX vs 7.8% PBO+MTX), consent withdrawal (5.3% vs 6.8%) and 'other' (including some mandatory withdrawals at Weeks 24 and 36). BL characteristics were balanced between treatment arms, with most patients presenting with high disease activity (DAS28(ESR) \>5.1), erosions and positivity for RF and ACPA early in the disease course (within 4 months after diagnosis; [table 1](#ANNRHEUMDIS2015209057TB1){ref-type="table"}).

###### 

Summary of baseline demographics and characteristics

  ---------------------------------------------------------------------------------------------------------------
  Characteristic                                     PBO+MTX\             CZP+MTX\            All patients\
                                                     n=213                n=655               n=868
  -------------------------------------------------- -------------------- ------------------- -------------------
  Mean age, years (SD)                               51.2 (13.0)          50.4 (13.6)         50.6 (13.5)

  Female, n (%)                                      170 (79.8)           497 (75.9)          667 (76.8)

  BMI (kg/m^2^)                                                                               

   n                                                 213                  652                 865

   Mean (SD)                                         28.8 (6.4)           28.0 (6.0)          28.2 (6.1)

  Region, n (%)                                                                               

   Europe and Australia                              107 (50.2)           354 (54.0)          461 (53.1)

   Latin and North America                           106 (49.8)           301 (46.0)          407 (46.9)

  Systemic corticosteroids, n (%)^a^                 64 (29.5)            222 (33.7)          286 (32.6)

  DAS28(ESR), mean (SD)                              6.8 (0.9)            6.7 (0.9)           6.7 (0.9)

   Moderate disease activity: \>3.2 to ≤5.1, n (%)   10 (4.7)             20 (3.1)            30 (3.5)

   High disease activity: \>5.1, n (%)               203 (95.3)           635 (96.9)          838 (96.5)

  SDAI, mean (SD)                                    44.8 (13.9)          43.5 (13.6)         43.8 (13.7)

  CDAI, mean (SD)                                    42.6 (12.9)          41.3 (12.5)         41.6 (12.6)

  HAQ-DI, mean (SD)                                  1.7 (0.6)            1.6 (0.6)           1.6 (0.6)

  TJC (28 joints), mean (SD)                         16.2 (6.5)           15.6 (6.5)          15.8 (6.5)

  SJC (28 joints), mean (SD)                         13.0 (5.6)           12.4 (5.5)          12.5 (5.5)

  ESR (mm/h), median (min, max)                      44.0 (10.0, 135.0)   42.0 (2.0, 150.0)   43.0 (2.0, 150.0)

  CRP (mg/L), median (min, max)                      10.5 (0.3, 243.2)    11.1 (0.2, 231.1)   11.1 (0.2, 243.2)

  Months since RA was first diagnosed, mean (SD)     2.9 (2.9)            2.9 (4.6)           2.9 (4.3)

   \>4 months, mean (SD)                             7.1 (2.5)^b^         7.6 (7.8)^c^        7.4 (6.8)

   ≤4 months, mean (SD)                              1.4 (1.0)^d^         1.4 (1.0)^e^        1.4 (1.0)

  Months since first RA symptom, mean (SD)^f^        9.6 (11.8)^g^        12.4 (32.3)^h^      11.7 (28.6)

  RF positive (≥14 IU/mL), n (%)                     206 (96.7)           634 (96.8)          840 (96.8)

  ACPA positive (≥7 IU/mL), n (%)                    182 (85.4)           546 (83.4)          728 (83.9)

  mTSS, median (min, max)                            2.8 (0, 161)         3.0 (0, 130)        3.0 (0, 161)

   Mean (SD)                                         8.5 (17.5)           7.2 (13.8)          7.5 (14.8)

   \>4 months, median (min, max)                     5.0 (0, 106)^i^      3.0 (0, 38)^j^      −

   ≤4 months, median (min, max)                      2.3 (0, 161)^k^      2.5 (0, 130)^l^     −

  Erosion score, median (min, max)                   1.5 (0, 68)          1.5 (0, 69)         1.5 (0, 69)

  JSN, median (min, max)                             0 (0, 94)            0 (0, 76)           0 (0, 94)

  Presence of erosions, n (%)                        169 (79.3)           506 (77.3)          675 (77.8)
  ---------------------------------------------------------------------------------------------------------------

^a^Safety set, all other data are reported for full analysis set; ^b^n=56; ^c^n=153; ^d^n=157; ^e^n=502; ^f^data were collected retrospectively; ^g^n=208; ^h^n=631; ^i^n=43; ^j^n=118; ^k^n=120 and ^l^n=410.

ACPA, anticitrullinated peptide antibody; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; CZP, certolizumab pegol; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index.

![Patient disposition in the C-EARLY study. ^a^'Other' included some mandatory withdrawals at Weeks 24 and 36. In addition, two patients in the certolizumab pegol (CZP)+methotrexate (MTX) group were randomised in error, were not dosed and were withdrawn shortly afterwards as screen failures (these two subjects were included in the RS). Patients completed Week 52 if they had a Week 52 visit. FAS, full analysis set; PBO, placebo; RAD, radiographic set; RS, randomised set; SS, safety set.](annrheumdis-2015-209057f01){#ANNRHEUMDIS2015209057F1}

The mean maximum-tolerated dose of MTX (optimised MTX) achieved by Week 8 was 21 mg/week for the CZP group and 22 mg/week for the PBO group.

Efficacy {#s3b}
--------

The C-EARLY study met its primary endpoint: treatment of DMARD-naïve patients with RA with CZP+MTX significantly reduced disease activity and sustained clinical response compared with PBO+MTX. At Week 52, sREM was achieved by 28.9% CZP+MTX patients versus 15.0% PBO+MTX patients (p\<0.001), while sLDA was achieved by 43.8% CZP+MTX patients versus 28.6% in the PBO+MTX group (p\<0.001; [figure 2](#ANNRHEUMDIS2015209057F2){ref-type="fig"}A). The similar results obtained for the sensitivity analysis on the 52-week completer group (sREM: 37.8% CZP+MTX vs 22.4% PBO+MTX, p\<0.001; sLDA: 57.4% CZP+MTX vs 42.7% PBO+MTX, p=0.002) suggest that withdrawals did not significantly bias the results.

![(A) Sustained remission (sREM), sustained low disease activity (sLDA) and American College of Rheumatology (ACR)50 response at Week 52. The results are shown for FAS; sREM was defined as DAS28(ESR) \<2.6 at Week 40 and Week 52; sLDA was defined as DAS28(ESR) ≤3.2 at Week 40 and Week 52; non-responder imputation was used for missing data and ORs were estimated by logistic regression adjusted for treatment, geographic region and rheumatoid arthritis (RA) disease duration at baseline (BL). (B) The mean change from BL in van der Heijde modified total Sharp score (mTSS), erosion score and joint space narrowing at Week 52. The results are shown for RAD. Missing data (for patients who withdrew early) were imputed by linear extrapolation; data were analysed by analysis of covariance on the ranks with treatment, geographic region and RA disease duration at BL as factors and BL rank value as covariate; p values for erosion score and joint space narrowing are nominal only. CZP, certolizumab pegol; FAS, full analysis set; MTX, methotrexate; OR, odds ratio; PBO, placebo; RAD, radiographic set.](annrheumdis-2015-209057f02){#ANNRHEUMDIS2015209057F2}

All secondary endpoints showed statistically significant differences for CZP+MTX versus PBO+MTX at Week 52, respectively: more patients achieved ACR50 response (61.8% vs 52.6%, p=0.023; [figure 2](#ANNRHEUMDIS2015209057F2){ref-type="fig"}A), greater improvements in physical function (CFB in HAQ-DI: −1.00 vs −0.82, p\<0.001; HAQ-DI normative function: 48.1% vs 35.7%, p=0.002) and significant inhibition of radiographic progression (CFB in mTSS: 0.2 vs 1.8, p\<0.001, [figure 2](#ANNRHEUMDIS2015209057F2){ref-type="fig"}B). Mean changes from BL in joint erosion score and joint space narrowing score were smaller for CZP+MTX versus PBO+MTX ([figure 2](#ANNRHEUMDIS2015209057F2){ref-type="fig"}B). The proportion of patients with radiographic non-progression was significantly higher for CZP+MTX than for PBO+MTX ([figure 3](#ANNRHEUMDIS2015209057F3){ref-type="fig"}). When alternative definitions of remission were used, the proportion of patients in clinical remission at Week 52 by DAS28(ESR) \<2.6, ACR/EULAR criteria, CDAI ≤2.8 and SDAI ≤3.3 was significantly greater for CZP+MTX compared with PBO+MTX ([figure 4](#ANNRHEUMDIS2015209057F4){ref-type="fig"}A).

![Cumulative probability plot of mean change from baseline in van der Heijde modified total Sharp score (mTSS) at Week 52. RAD; linear extrapolation; p values are nominal only. CZP, certolizumab pegol; MTX, methotrexate; PBO, placebo; RAD, radiographic set.](annrheumdis-2015-209057f03){#ANNRHEUMDIS2015209057F3}

![(A) Proportion of patients in remission (various definitions) at Week 52. The results are shown for FAS, non-responder imputation was used for missing data and ORs are estimated by logistic regression; p values shown are nominal only. (B) The mean change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) by visit. FAS, last observation carried forward; nominal p values are estimated by logistic regression: \*p≤0.05, ^†^p\<0.001. (C) Proportion of patients in DAS28(ESR) low disease activity by visit. FAS, NRI; nominal p values are estimated by logistic regression: \*p≤0.05, ^†^p\<0.001. ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CZP, certolizumab pegol; EULAR, European League Against Rheumatism; FAS, full analysis set; LS, least squares; MTX, methotrexate; OR, odds ratio; PBO, placebo; SDAI, Simplified Disease Activity Index.](annrheumdis-2015-209057f04){#ANNRHEUMDIS2015209057F4}

Physical function (as measured by HAQ-DI) improved over time in the CZP+MTX group through Week 52; a similar trend was observed in the PBO+MTX group, but with a consistently smaller improvement from BL at each time point ([figure 4](#ANNRHEUMDIS2015209057F4){ref-type="fig"}B and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2).

A higher proportion of patients achieved LDA (DAS28(ESR) ≤3.2) at individual time points from Week 2 (8.4% vs 1.4%, p=0.002) in the CZP+MTX group compared with the PBO+MTX group, with the absolute percentage and mean difference between groups slowly increasing to Week 52 (54.7% CZP+MTX vs 39.4% PBO+MTX, p\<0.001; [figure 4](#ANNRHEUMDIS2015209057F4){ref-type="fig"}C and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S3).

ACR20/50/70 response rates showed a separation of CZP+MTX treatment from PBO+MTX as early as Week 2 and was sustained to Week 52 for ACR50/70 ([figure 5](#ANNRHEUMDIS2015209057F5){ref-type="fig"}). From Week 6 onwards, there was no statistical difference between CZP+MTX and PBO+MTX in ACR20 response.

![Percentage of patients with American College of Rheumatology (ACR)20/50/70 response by visit. The results are shown for FAS and non-responder imputation was used for missing data; nominal p value between groups are estimated by logistic regression: \*p≤0.05 at Weeks 2, 4 and 40 (ACR20); ^†^p≤0.05 at Weeks 2, 4, 6, 8, 12, 20, 40 and 52 (ACR50); ^‡^p≤0.05 at all time points (ACR70). CZP, certolizumab pegol; FAS, full analysis set; MTX, methotrexate; PBO, placebo.](annrheumdis-2015-209057f05){#ANNRHEUMDIS2015209057F5}

A greater decrease in disease activity (measured by CFB in DAS28(ESR)) was observed for CZP+MTX compared with PBO+MTX as early as Week 2 (p\<0.001) and continued to Week 52 (the mean CFB (SE) at Week 52: −3.6 (0.1), CZP+MTX vs −3.0 (0.1) PBO+MTX, p\<0.001; mean DAS28(ESR) values are shown in [table 2](#ANNRHEUMDIS2015209057TB2){ref-type="table"}). Similar trends from Week 2 through Week 52 were observed in CDAI, SDAI, TJC, SJC, ESR and CRP ([table 2](#ANNRHEUMDIS2015209057TB2){ref-type="table"}).

###### 

Mean disease activity at key study visits

                         Baseline              Week 2                Week 12             Week 24               Week 52
  --------------------- --------------------- -------------------- -------------------- -------------------- --------------------
  DAS28(ESR)                                                                                                 
   PBO+MTX (SD)         6.80 (0.91)           5.91 (1.28)          4.43 (1.46)          4.07 (1.44)          3.77 (1.68)
   CZP+MTX (SD)         6.70 (0.89)           5.06 (1.27)          3.88 (1.44)          3.54 (1.47)          3.11 (1.58)
   p Value (CFB)        −                     \<0.001              \<0.001              \<0.001              \<0.001
  CDAI                                                                                                       
   PBO+MTX (SD)         42.64 (12.87)         31.52 (14.85)        17.20 (13.69)        14.11 (12.99)        13.08 (13.72)
   CZP+MTX (SD)         41.28 (12.52)         23.74 (12.87)        13.33 (11.99)        10.79 (11.27)        8.71 (11.65)
   p Value (CFB)        −                     \<0.001              \<0.001              0.001                \<0.001
  SDAI                                                                                                       
   PBO+MTX (SD)         44.79 (13.91)         33.38 (15.84)        18.32 (14.39)        15.08 (13.65)        14.05 (14.29)
   CZP+MTX (SD)         43.46 (13.56)         24.41 (13.08)        14.10 (12.63)        11.55 (12.00)        9.43 (12.41)
   p Value (CFB)        −                     \<0.001              \<0.001              \<0.001              \<0.001
  TJC                                                                                                        
   PBO+MTX (SD)         16.22 (6.45)          12.37 (7.28)         6.20 (6.32)          5.08 (6.09)          4.76 (6.10)
   CZP+MTX (SD)         15.61 (6.48)          9.21 (6.76)          5.13 (5.86)          4.08 (5.63)          3.27 (5.39)
   p Value (CFB)        −                     \<0.001              0.055                0.060                0.002
  SJC                                                                                                        
   PBO+MTX (SD)         13.04 (5.64)          8.99 (6.02)          5.09 (5.38)          3.89 (4.58)          3.60 (4.51)
   CZP+MTX (SD)         12.37 (5.48)          6.77 (4.86)          3.25 (4.24)          2.61 (3.83)          2.06 (3.94)
   p Value (CFB)        −                     \<0.001              \<0.001              \<0.001              \<0.001
  ESR\*                                                                                                      
   PBO+MTX (min, max)   44.00 (10.0, 135.0)   41.00 (4.0, 140.0)   30.00 (1.0, 100.0)   30.00 (2.0, 137.0)   21.50 (2.0, 110.0)
   CZP+MTX (min, max)   42.00 (2.0, 150.0)    29.00 (1.0, 130.0)   22.00 (0.0, 150.0)   20.00 (0.0, 150.0)   17.00 (0.0, 150.0)
   p Value (CFB)        −                     \<0.001              \<0.001              \<0.001              \<0.001
  CRP\*                                                                                                      
   PBO+MTX (min, max)   10.51 (0.3, 243.2)    8.35 (0.3, 231.2)    4.69 (0.2, 157.8)    3.74 (0.2, 157.8)    3.96 (0.2, 157.8)
   CZP+MTX (min, max)   11.14 (0.2, 231.1)    2.17 (0.1, 237.2)    2.33 (0.1, 170.6)    2.05 (0.2, 251.8)    2.07 (0.1, 251.8)
   p Value (CFB)        −                     \<0.001              \<0.001              \<0.001              \<0.001

\*Median values; PBO+MTX n=213, CZP+MTX n=655; p values are nominal and describe the difference in CFB between the two study arms at each study visit; LOCF; FAS.

CFB, change from baseline; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; CZP, certolizumab pegol; ESR, erythrocyte sedimentation rate; FAS, full analysis set; LOCF, last observation carried forward; MTX, methotrexate; PBO, placebo; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count.

Subgroup analyses {#s3c}
-----------------

Analyses of subgroups defined by disease duration were carried out on the primary and secondary endpoints. For almost all endpoints, differences were in favour of CZP+MTX for patients with both ≤4 months (75.9% of patients) and \>4 months (24.1% of patients) since RA diagnosis, although for ACR50 in the \>4 months subgroup, no difference was observed between CZP+MTX and PBO+MTX. Forest plots demonstrated that patients in the ≤4 months subgroup had a greater response to CZP treatment (online [supplementary figure](#SM1){ref-type="supplementary-material"} S4 presents key categorical endpoints and forest plots; online [supplementary figure](#SM1){ref-type="supplementary-material"} S5 details mean changes from BL in mTSS; interpretation was limited due to the low number of patients in the \>4 months subgroups).

According to the logistic regression model, improvements in sREM with CZP+MTX versus PBO+MTX differed by geographical region, with greater improvements seen in Europe and Australia (38.4% CZP+MTX vs 16.8% PBO+MTX; OR=3.07, 95% CI (1.77 to 5.34), p\<0.001) than in Latin and North America (17.6% CZP+MTX vs 13.2% PBO+MTX; OR=1.43, 95% CI (0.75 to 2.70), p=0.28).

Safety {#s3d}
------

The incidence of AEs was similar for both treatment arms ([table 3](#ANNRHEUMDIS2015209057TB3){ref-type="table"}). The most frequently reported AEs in the CZP+MTX group were nausea, upper respiratory tract infection, urinary tract infection, nasopharyngitis, headache and increased levels of alanine aminotransferase (MedDRA preferred terms). Withdrawals due to AEs occurred for 57 (8.6%) CZP+MTX patients versus 20 (9.2%) PBO+MTX patients. The overall rates of SAEs were similar between treatment groups (CZP+MTX: 70 (10.6%); PBO+MTX: 20 (9.2%)).

###### 

Summary of AEs

  -----------------------------------------------------------------------------------------------------------------------------------
                                                          PBO+MTX\     CZP+MTX\                              
                                                          n=217        n=659                                 
  ------------------------------------------------------- ------------ ------------------------ ------------ ------------------------
  Any TEAE (≥5% in any SOC)                               158 (72.8)   195.6 (166.3 to 228.7)   525 (79.7)   250.8 (229.8 to 273.2)

   Blood and lymphatic system disorders                   13 (6.0)     6.9 (3.7 to 11.8)        45 (6.8)     7.8 (5.7 to 10.4)

   Eye disorders                                          13 (6.0)     7.0 (3.8 to 12.0)        24 (3.6)     4.1 (2.6 to 6.1)

   Gastrointestinal disorders                             53 (24.4)    34.0 (25.5 to 44.5)      206 (31.3)   44.7 (38.8 to 51.3)

   General disorders and administration site conditions   27 (12.4)    15.4 (10.2 to 22.5)      108 (16.4)   20.2 (16.6 to 24.4)

   Infections and infestations                            76 (35.0)    52.7 (41.5 to 66.0)      298 (45.2)   71.8 (63.9 to 80.4)

   Injury, poisoning and procedural complications         15 (6.9)     8.2 (4.6 to 13.5)        62 (9.4)     10.9 (8.4 to 14.0)

   Investigations                                         42 (19.4)    25.2 (18.2 to 34.1)      137 (20.8)   26.4 (22.1 to 31.2)

   Metabolism and nutrition disorders                     12 (5.5)     6.5 (3.3 to 11.3)        57 (8.6)     10.0 (7.6 to 13.0)

   Musculoskeletal and connective tissue disorders        36 (16.6)    20.5 (14.4 to 28.4)      114 (17.3)   21.2 (17.5 to 25.5)

   Nervous system disorders                               26 (12.0)    14.9 (9.7 to 21.8)       92 (14.0)    17.1 (13.8 to 20.9)

   Respiratory, thoracic and mediastinal disorders        22 (10.1)    12.3 (7.7 to 18.6)       76 (11.5)    13.6 (10.7 to 17.0)

   Skin and subcutaneous tissue disorders                 31 (14.3)    18.2 (12.4 to 25.8)      119 (18.1)   22.5 (18.6 to 26.9)

   Vascular disorders                                     9 (4.1)      4.8 (2.2 to 9.2)         39 (5.9)     6.7 (4.8 to 9.2)

  Serious TEAEs, n (%)                                    20 (9.2)     10.7 (6.6 to 16.6)       70 (10.6)    12.1 (9.4 to 15.2)

   Infections and infestations                            7 (3.2)      3.7 (1.5 to 7.6)         20 (3.0)     3.3 (2.0 to 5.2)

   *Active tuberculosis (TB)*\*                           0 (0.0)      −                        1 (0.2)      0.2 (0.0 to 0.9)

  Drug-related TEAEs                                      69 (31.8)    −                        278 (42.2)   −

  TEAEs leading to discontinuation                        20 (9.2)     10.6 (6.5 to 16.4)       57 (8.6)     9.6 (7.3 to 12.4)

  TEAEs requiring dose change of MTX                      14 (6.5)     −                        73 (11.1)    −

  TEAEs leading to death                                  1 (0.5)      0.5 (0.0 to 2.9)         2 (0.3)      0.3 (0.0 to 1.2)
  -----------------------------------------------------------------------------------------------------------------------------------

\*Included both pulmonary TB and gastrointestinal TB in the same patient, diagnosis not confirmed by PCR. SS. n, number of patients reporting ≥1 AE in that category. A TEAE was defined as an AE starting on or after the date of first study medication administration and up to 70 days after the last (most recent) CZP or PBO dose. AEs with a missing relationship to study medication were counted as related. MedDRA v17.0.

AE, adverse event; CZP, certolizumab pegol; IR, incidence rate; MTX, methotrexate; PBO, placebo; SOC, system organ class; SS, safety set; TEAE, treatment emergent adverse event.

The IR of infection was higher with CZP+MTX (71.8/100 PY, 95% CI (63.9 to 80.4)) than PBO+MTX (52.7/100 PY, 95% CI (41.5 to 66.0)), while the incidence of serious infection was similar in both groups (3.3/100 PY (2.0, 5.2) vs 3.7/100 PY (1.5, 7.6), respectively). The IR of opportunistic infections was higher in the CZP+MTX group (0.2/100 PY, 95% CI (0.0 to 0.9)) with no cases in the PBO+MTX group. One case of disseminated mycobacterium infection was reported in the CZP+MTX group. The mycobacterial strain was not characterised by PCR.

There were two deaths reported in the CZP+MTX group: one stroke, not considered related to study medication, and one case of disseminated, non-characterised, mycobacterium infection (reported above) primarily localised in the peritoneum (peritonitis with extensive granulomas which stained positive for acid-fast bacillus) with acute respiratory distress, considered by the investigator to be study medication related. Notably, the BL chest X-ray and QuantiFERON test were both negative. The one death in the PBO+MTX group was not considered to be related to study medication (respiratory failure).

Discussion {#s4}
==========

C-EARLY is the first report of a double-blind, randomised PBO-controlled study assessing the efficacy and safety of CZP+optimised MTX in DMARD-naïve patients with early RA with poor prognostic factors, using a stringent primary outcome of sREM. These data demonstrate that CZP+MTX combination therapy results in a significantly higher proportion of patients achieving sREM than those treated with PBO+MTX, even when using a 'treat-to-tolerance' dosing strategy for MTX. Significant improvements in physical function and inhibition of structural damage were observed for CZP+MTX patients. Consequently, for patients with poor prognostic factors for severe disease progression, treating early and aggressively may represent a unique opportunity to achieve maximal clinical benefit.

Advances in the treatment options for RA, including DMARDs and biologic DMARDs/anti-TNFs, have made clinical remission and radiographic non-progression an achievable target.[@R12] In this study, MTX titration was an important component of treatment and ensured that each patient received the maximum-tolerated MTX dose within the first 8 weeks (between ≥15 and ≤25 mg/week), which we refer to as optimised MTX. To our knowledge, there are no previous studies in MTX-naïve or DMARD-naïve patients with RA where MTX doses have been optimised per-protocol to the levels achieved in C-EARLY. This optimisation may have been responsible, in part, for the response observed for the PBO+MTX and CZP+MTX arms. Optimisation of MTX is not specifically stated in treat-to-target guidelines; however, the mean doses achieved are consistent with international recommendations.[@R13]

In addition to sREM, this study also evaluated the rate of remission using alternative remission criteria, including DAS28(ESR), CDAI, SDAI and ACR/EULAR criteria, with superior results consistently observed for CZP+MTX over PBO+MTX, supporting the reliability of the recently validated ACR/EULAR remission definition.[@R14] In the C-EARLY trial, despite receiving optimised MTX, a significant proportion of patients were not in remission at Week 52 and an even smaller proportion achieved the primary outcome of sREM. Although patients generally responded well to MTX, which is expected in a DMARD-naïve population of patients, they responded significantly better to CZP, confirming the clinical relevance of our findings.

Treatment of patients very early in the pathogenesis of disease is associated with significantly reduced joint destruction and better clinical outcomes.[@R15] The analysis of radiographic data in C-EARLY demonstrates that CZP+MTX therapy can inhibit structural damage significantly more than MTX alone---the percentage of patients with radiographic non-progression was significantly higher in the CZP+MTX group compared with the PBO+MTX group. These results are consistent with the C-OPERA trial in Japanese patients with early RA, which showed that CZP+MTX treatment results in greater inhibition of structural damage and higher clinical remission rates than PBO+MTX.[@R9]

While DAS(ESR)\<2.6 is a validated measure of clinical remission, consensus has not yet been reached on what constitutes sREM. Until now, the two RA clinical trials that have used sREM as the primary endpoint chose two different definitions. These trials were an open-label study evaluating etanercept tapering[@R6] and an open-label study evaluating abatacept withdrawal.[@R16] We defined sREM as DAS(ESR) \<2.6 at Weeks 40 and 52 of treatment. The use of two time points 12 weeks apart was meant to reflect RA management goals used in real-world clinical practice.[@R3]

The rates of sREM observed in C-EARLY (28.9% for the CZP+MTX arm) were lower than those initially estimated in the power analysis, which were based on Week 52 remission rates of the etanercept COMET trial (50%).[@R17] This is most likely a consequence of the use of sREM, which is a more rigorous endpoint than clinical remission; this is supported by C-EARLY Week 52 remission rates (42% for the CZP+MTX arm), which were comparable with the remission rates observed in COMET.

Overall, the results from C-EARLY suggest that it is possible to achieve sREM more frequently with combined CZP+MTX treatment than with MTX alone in DMARD-naïve patients with RA. Consistent with our results, other studies have demonstrated greater efficacy of anti-TNFs in combination with MTX in early RA. These have included infliximab+MTX,[@R18] adalimumab+MTX,[@R19] etanercept+MTX[@R17] [@R20] and golimumab+MTX.[@R21]

No new safety signals for CZP+MTX were observed and there was no increase in infection relative to other anti-TNFs in equivalent patient populations with RA.[@R7] [@R8] No increase in overall AEs, SAEs or serious infection events (SIEs) in patients treated with CZP+MTX was seen compared with PBO+MTX. As patients were DMARD-naïve (including MTX) at study entry, their tolerance to MTX treatment could not be anticipated. Thus, the incidence of AEs observed in this study may be partly attributed to the optimised MTX dose. The IR of SIEs with CZP+MTX in this study (3.3/100 PY) was comparable with those reported for other anti-TNFs in combination with MTX in similar patient populations with early RA: adalimumab+MTX (2.9/100 PY)[@R19] and infliximab+MTX (5.4/100 PY).[@R22] The single CZP-related death in this study occurred in a 65-year-old patient of Indian origin, with hypertension and diabetes mellitus. The patient died of cardiorespiratory failure and acute respiratory distress syndrome, secondary to septic shock caused by bowel perforations. Acid-fast bacillus stains of the gut and saliva were positive. This, in conjunction with the gut pathology, led to a diagnosis of disseminated, non-characterised, mycobacterium infection; the QuantiFERON test was negative and there was no PCR confirmation of TB.

We conclude that there is a positive benefit--risk ratio associated with CZP treatment in combination with MTX as initial therapy in DMARD-naïve patients within a year of diagnosis of severe, active RA. The beneficial effect of earlier treatment with biologics specifically in patients with poor prognostic factors may be an important consideration in determining the timing of treatment initiation in specific subgroups of patients. Of note, an aggressive combination of CZP with a 'treat-to-tolerance' strategy for MTX at an early stage of disease may contribute to overcome the currently perceived 'efficacy ceiling' for anti-TNFs.

**Correction notice:** This article has been corrected since it was published Online First. In the penultimate paragraph of the Discussion section the 'IR of SIEs with CZP+MTX in this study' has been corrected to '(3.3/100 PY)'.
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